"If you have a hard time falling asleep or staying asleep for three out of seven nights each week for a period of three months, you are probably suffering from insomnia." says Dr. Russell Rosenberg, Chief Science Officer and CEO at NeuroTrials Research in Atlanta, GA.
In this podcast, Rosenberg explains to the listeners that insomnia is more prevalent now than ever. "Covid-19 has definitely caused a spike in sleep disturbances in this country," says Rosenberg. He urges listeners to speak with (virtually if necessary) their primary care physician and discuss their sleep concerns. There are medications that can help.
Marion asks Rosenberg to talk the pros and cons of a new medication that was just approved for use in the USA called Dayvigo or Lemborexant by Eisai.
Rosenberg explains that "Dayvigo, a schedule IV controlled substance, is a dual orexin reception antagonist that works differently than other sleep medications because it blocks the orexin signals in the brain that are believed to play a role in wakefulness." He encourages healthcare providers to look at Dayvigo as an option for their patients.
Rosenberg reminds listeners that there is the "potential for next day somnolence" and that driving ability was impaired in some subjects taking 10 mg dose.
Rosenberg concludes the podcast with two comments: "Anyone with narcolepsy, a sleep disorder that results in daytime sleepiness, would be adversely affected by Dayvigo." If you are experiencing excessive daytime sleepiness, speak with your primary physician and seek a sleep doctor. Second, "do not mix Dayvigo with alcohol as it could be dangerous and potentially life threatening."
Podden och tillhörande omslagsbild på den här sidan tillhör The Sleep Forum. Innehållet i podden är skapat av The Sleep Forum och inte av, eller tillsammans med, Poddtoppen.
